subscribeSubscribe
EU regulator clears Idorsia’s Jeraygo to resistant hypertension

EU regulator clears Idorsia’s Jeraygo to resistant hypertension
Https://ml-eu.globenewswire.com/Resource/Download/27025b97-6462-4b44-a696-d2c8d3672ae3 PRESS RELEASE
02 Jul 2024
Share Share
Aprocitentan PRECISION Data At European Hypertension Congress 2024

Aprocitentan PRECISION Data At European Hypertension Congress 2024
GLOBENEWSWIRE
30 May 2024
Share Share
JERAYGO (aprocitentan) Recommended for EU Approval in Resistant HTN

JERAYGO (aprocitentan) Recommended for EU Approval in Resistant HTN
GLOBENEWSWIRE
26 Apr 2024
Share Share
US FDA approves Idorsia`s once-daily TRYVIO (aprocitentan)

US FDA approves Idorsia`s once-daily TRYVIO (aprocitentan)
PRESS RELEASE
21 Mar 2024
Share Share
US FDA approves TRYVIO (aprocitentan) for the treatment of high blood pressure

US FDA approves TRYVIO (aprocitentan) for the treatment of high blood pressure
PR NEWSWIRE
20 Mar 2024
Share Share
J&J pulls out of Idorsia deal for hypertension drug

J&J pulls out of Idorsia deal for hypertension drug
PHARMAPHORUM
07 Sep 2023
Share Share
New Phase 3 data with aprocitentan has been presented

New Phase 3 data with aprocitentan has been presented
GLOBENEWSWIRE
26 Jun 2023
Share Share
Idorsia submits a NDA to the US FDA for aprocitentan

Idorsia submits a NDA to the US FDA for aprocitentan
GLOBENEWSWIRE
20 Dec 2022
Share Share
Idorsia submits a new drug application to the FDA

Idorsia submits a new drug application to the FDA
REUTERS
20 Dec 2022
Share Share
The Lancet & AHA late-breaking session reports significant & effect aprocitentan

The Lancet & AHA late-breaking session reports significant & effect aprocitentan
GLOBENEWSWIRE
07 Nov 2022
Share Share